All News

Found 3,193 articles

• Compugen Ltd. Lets The Cat Out Of The Bag, Discloses Discovery Of Five Potential Cancer Targets For New Program

  12/12/2013

• Covagen Locks In $47.2 Million Series B

  12/10/2013

• ImmunoGen, Inc. Announces Activity Reported With SAR3419 Plus Rituxan In Difficult-To-Treat Patient Population

  12/10/2013

• ImaginAb, Inc. Expands Scientific Advisory Board

  11/25/2013

• ImmunoGen, Inc. Announces Approval Of Roche’s Kadcyla® In The European Union

  11/20/2013

• OXiGENE Announces Preclinical Data Presentation On Novel Anticancer Compounds, Benzosuberenes, Demonstrating Potent Anti-Proliferative Activity

  11/18/2013

• ImmunoGen, Inc. Named One Of The Boston Globe’s Top Places To Work

  11/18/2013

• Sangamo BioSciences, Inc. Announces Presentation Of Clinical Data From Alzheimer's Disease Program

  11/15/2013

• Sorrento Therapeutics, Inc. Enters Into Definitive Agreement To Acquire Antibody Drug Conjugation Technology

  11/14/2013

• Stemline Therapeutics, Inc. Announces Five Presentations At The American Society of Hematology Annual Meeting, Including A Clinical Update Of SL-401 In BPDCN

  11/14/2013

• ImmunoGen, Inc. Is On A Roll, Inks Fifth New License Agreement Of 2013

  11/11/2013

• ImmunoGen, Inc. Announces Webcast Of Presentations At Upcoming Investor Conferences

  11/11/2013

• ImmunoGen Discontinues Study as Lung Cancer Drug Flops; Stock Crashes -18.97% at Market Close (November 5, 2013)

  11/6/2013

• ADC Therapeutics Licenses Proprietary Antibodies From Five Prime Therapeutics, Inc., Adds an Additional Proprietary ADC Development Program in Oncology

  11/5/2013

• PRECOS Announces World Pharma Congress 2013 Co-Presentation With Crown Bioscience, Inc. Illustrating the Benefits of Clinically Relevant PDX Models for Oncology Drug Discovery

  11/1/2013

• ImmunoGen, Inc. Reports First Quarter Fiscal Year 2014 Financial Results and Provides Quarterly Update

  10/25/2013

• ImmunoGen, Inc. Reports on Additions to Its Industry-Leading ADC Technology Portfolio at ImmunoGen, Inc.-National Cancer Institute-EORTC Conference

  10/23/2013

• Mersana Therapeutics, Inc. Forms Scientific Advisory Board to Support Development of Next-Generation Antibody-Drug Conjugates

  10/21/2013

• ImmunoGen, Inc. Announces SAR566658 Clinical Findings Reported at American Association for Cancer Research-National Cancer Institute-EORTC Conference

  10/21/2013

• ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2014 Financial Results

  10/18/2013